Monopar Therapeutics SG&A Expense (Quarterly) Analysis

Monopar Therapeutics Inc (MNPR)

0.66 +0.01 (+1.54%) USD | NASDAQ | May 02, 16:00

0.66 0.00 (0.00%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2017. Upgrade now.

Date	Value
December 31, 2023	0.8764M
September 30, 2023	0.7495M
June 30, 2023	0.7335M
March 31, 2023	0.8717M
December 31, 2022	0.806M
September 30, 2022	0.6751M
June 30, 2022	0.6849M
March 31, 2022	0.7793M
December 31, 2021	0.6984M
September 30, 2021	0.6317M
June 30, 2021	0.616M
March 31, 2021	0.6879M
December 31, 2020	0.6284M
September 30, 2020	0.3921M

Date	Value
June 30, 2020	0.6316M
March 31, 2020	0.7916M
December 31, 2019	0.6411M
September 30, 2019	0.5396M
June 30, 2019	0.6028M
March 31, 2019	0.5717M
December 31, 2018	0.4054M
September 30, 2018	0.3638M
June 30, 2018	0.3473M
March 31, 2018	0.4401M
December 31, 2017	0.4275M
September 30, 2017	0.2152M
June 30, 2017	0.2834M
March 31, 2017	0.2401M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

0.3921M

Minimum

Sep 2020

0.8764M

Maximum

Dec 2023

0.6862M

Average

0.6849M

Median

Jun 2022

SG&A Expense (Quarterly) Benchmarks